Androgen Receptor Enhances the Efficacy of Sorafenib Against Hepatocellular Carcinoma Through Enriched EpCAM Stemness
Hsueh‐Chou Lai(China Medical University), Wei-Chun Chang(China Medical University), Wei-Min Chung(China Medical University), Long‐Bin Jeng(National Cancer Center), Chun-Chieh Yeh(China Medical University), Yu-Ting Su(China Medical University), Chun-Mien Chang(Southwestern Medical Center), Pei-Yin Liao(China Medical University), Wen‐Lung Ma(Asia University)
Cited by 6
Related Papers
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques
|Nature Biomedical Engineering|2018|363
Androgen Receptor Is a New Potential Therapeutic Target for the Treatment of Hepatocellular Carcinoma
|Gastroenterology|2008|253
Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor
|Hepatology|2008|207
Omega-3 Fatty Acids in the Prevention of Interferon-Alpha-Induced Depression: Results from a Randomized, Controlled Trial
|Biological Psychiatry|2014|203